Shared Neurobiological Pathways Between Type 2 Diabetes and Depressive Symptoms: a Review of Morphological and Neurocognitive Findings

Current Diabetes Reports

Volumn 14, Issue 12, 2014, Pages 1-12

  Doyle, Todd ^a   Halaris, Angelos ^a   Rao, Murali ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biological mechanisms; Brain; Depression; Depressive symptoms; Hippocampus; Morphological and structural abnormalities; MRI; Neurocognitive deficits; Neurogenesis; Neuroplasticity; Prefrontal cortex; Type 2 diabetes; Volumetric

Indexed keywords

ADRENERGIC SYSTEM; BODY COMPOSITION; BRAIN REGION; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYPERACTIVITY; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROBIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; QUALITY OF LIFE; REVIEW; COGNITION; COMPLICATION; METABOLISM; NEUROIMAGING; PATHOPHYSIOLOGY; PSYCHOLOGY; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; COGNITION; COMORBIDITY; DEPRESSION; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; NEUROIMAGING;

EID: 84920872265     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0560-7     Document Type: Review

References (69)

1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069–78.
2. Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Care. 1993;16:1167–78.
3. de Groot M, Doyle T, Hockman E, Wheeler C, Pinkerman B, Shubrook J, et al. Depression among type 2 diabetes rural Appalachian clinic attendees. Diabetes Care. 2007;30:1602–4.
4. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000;23:934–42.
5. de Groot M, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30.
6. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes. Impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160:3278–85.
7. Jacobson AM, de Groot M, Samson JA. The effects of psychiatric disorders and symptoms on quality of life in patients with type I and type II diabetes. Qual Life Res. 1997;6(1):11–20.
8. Egede L, Osborn C. Role of motivation in the relationship between depression, self-care and glycemic control in adults with type 2 diabetes. Diabetes Educ. 2010;36(2):276–83.
9. Katon W, Von Korff M, Ciechanowski P, Russo J, Lin E, et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care. 2004;27:914–20.
10. Katon W, Rutter C, Simon G, Lin EB, Ludman E, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 2005;28:2668–72.
11. Simon G, von Korff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52:850–6.
12. Penckofer S, Doyle T, Byrn, M, Lustman PJ. State of the science: depression and type 2 diabetes. W J Nurs Res. 2014;1–25.
13. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan. Diabetes Care. 2008;31:2382–90.
14. Nefs G, Pouwer F, Denollet J, Pop V. The course of depressive symptoms in primary care patients with type 2 diabetes: results from the Diabetes, Depression, Type D Personality Zuidoost-Brabant (DiaDDZoB) study. Diabetologia. 2012;55:608–16.
15. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, et al. Type 2 diabetes as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia. 2010;53:2480–6.
16. Cosgrove MP, Sargeant LA, Griffin SJ. Does depression increase the risk of developing type 2 diabetes? Occup Med. 2008;58:7–14.
17. Champaneri S, Wand GS, Malhotra SS, Casagrande SS, Golden SH. Biological basis of depression in adults with diabetes. Curr Diabetes Rep. 2010;10:396–405.
18. Stuart MJ, Baune BT. Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev. 2012;36:658–76. Well written review paper that highlights several biological mechanisms associated with T2D and depression with a particular emphasis on cellular and molecular research.
19. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–23.
20. Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes. A meta-analysis. Diabetologia. 2006;49:837–45.
21. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.
22. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12:331–59.
23. Dantzer R, O’Connor JC, Freund GC, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature. 2008;9:46–7.
24. Doyle TA, de Groot M, Harris T, Schwartz F, Strotmeyer ES, Johnson KC, et al. Diabetes, depressive symptoms, and inflammation in older adults: results from the Health, Aging, and Body Composition Study. J Psychosom Res. 2013;75:419–24. First empirical study to confirm that previously hypothesized markers of inflammation are elevated in participants with both T2D and self-reported depressive symptoms to a greater degree than participants with either disorder alone or people without T2D and depressive symptoms.
25. Alvarez A, Faccioli J, Guinzbourg M, Castex MM, Bayon C, Masson W. Endocrine and inflammatory profiles in type 2 diabetic patients with and without major depressive disorder. BMC Res Notes. 2013;6:61. Provides corroborating evidence that previously hypothesized markers of inflammation are elevated in participants with both T2D and clinically diagnosed MDD as well as the first reported evidence that 24-hour urine free cortisol levels are higher among participants with both disorders compared to participants with T2D alone.
26. Fossati P, Radtchenko A, Boyer P. Neuroplasticity: from MRI to depressive symptoms. Eur Neuropsychopharmacol. 2004;14(5):S503–10.
27. Reagan L. Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications. Exp Neurol. 2012;233(1):68–78.
28. Ho N, Sommers MS, Lucki I. Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev. 2013;37:1346–62.
29. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbein J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dysfunct. 2009;24:27–53.
30. Koehl M, Abrous DN. A new chapter in the field of memory: adult hippocampal neurogenesis. Eur J Neurosci. 2011;33:1101–14.
31. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. A role for adult neurogenesis in spatial long-term memory. Neuroscience. 2011;130:843–52.
32. Black P. The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes, type II. Med Hypotheses. 2006;67:879–91.
33. Black PH. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun. 2003;17(5):350–64.
34. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8:367–81.
35. Konarski JZ, McIntyre RS, Kennedy SH, Rafi-Tari S, Soczynska JK, Ketter TA, et al. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord. 2008;10:1–37.
36. Eker C, Gonul AS. Volumetric MRI studies of the hippocampus in major depressive disorder: meanings of inconsistency and directions for future research. World J Biol Psychiatry. 2010;11:19–35.
37. Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatr. 2006;19(1):25–33.
38. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry. 2004;56(9):640–50.
39. Fontan-Lozano A, Saez-Cassanelli JL, Inda MC, de los Santos-Artaga M, Sierra-Dominguez SA, Lopez-Lluch G, et al. Caloric restriction increases learning consolidation and facilitates synaptic plasticity through mechanisms dependent on NR28 subunits of the NMDA receptor. J Neurosci. 2007;27:10185–95.
40. Morris RG. Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci. 2001;356:1453–65.
41. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression Anxiety. 2013;30:515–27. One of the most comprehensive reviews of cognitive deficits and functional outcomes in depression.
42. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci U S A. 2004;101:284–9.
43. Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584–7.
44. Ajilore O, Narr K, Rosenthal J, Pham D, Hamilton L, Watari K, et al. Regional cortical gray matter thickness differences associated with type 2 diabetes and major depression. Psychiatry Res. 2010;184(2):63–70. Demonstrated that volumetric changes were greatest among patients with T2D + MDD compared to other groups/controls; one of only a few recent investigations to collect data from patients with both T2D + MDD.
45. Anan F, Masaki T, Shimomura T, Fujiki M, Umeno Y, Eshima N, et al. High-sensitivity C-reactive protein is associated with hippocampus volume in nondementia patients with type 2 diabetes. Metab Clin Exp. 2011;60:460–6.
46. de Bresser J, Tiehuis AM, van den Berg E, Reijmer YD, Jongen C. & jaap Kappelle, L et al.: progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. Diabetes Care. 2010;33:1309–14.
47. Bruehl H, Wolf OT, Convit AA. Blunted cortisol awakening response and hippocampal atrophy in type 2 diabetes. Psychoneuroendocrinology. 2009a;34(6):815–21.
48. Bruehl H, Wolf OT, Sweat V, Tirsi A, Richardson S, Convit A. Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes. Brain Res. 2009;1280:186–94.
49. Brundel M, van den Heuvel M, de Bresser J, jaap Kappelle L, jan Biessels G. Cerebral cortical thickness in patients with type 2 diabetes. J Neurol Sci. 2010;299:126–30.
50. Cui X, Abduljalil A, Manor BD, Peng C, Novak V. Multi-scale glycemic variability: a link to gray matter atrophy and cognitive decline in type 2 diabetes. PLoS One. 2014;9(1):e86284.
51. van Elderen SGC, de Roos A, de Craen AJM, Westendorp RGJ, Blauw GJ, Jukema JW. Progression of brain atrophy and cognitive decline in diabetes: a 3-year follow-up. Neurology. 2010;75:997–1002.
52. Falvey CM, Rosano C, Simonsick EM, Harris T, Strotmeyer ES, Satterfield S. Macro- and microstructural magnetic resonance imaging indices associated with diabetes among community-dwelling older adults. Diabetes Care. 2013;36:677–82. Provides results on structural abnormalities in T2D patients compared to controls using one of the largest population-based studies to date, the Healthy, Aging, and Body Composition Study.
53. Hapel R, Onopa R, Convit A. Type 2 diabetes affects brain health differentially in men and women. Diabetes Metab Res Rev. 2012;28(1):76–83.
54. Hayaski K, Kurioka S, Yamaguchi T, Morita M, Kanazawa I, Takase H, et al. Association of cognitive dysfunction with hippocampal atrophy in elderly Japanese people with type 2 diabetes. Diabetes Res Clin Pract. 2011;94:180–5.
55. Kamiyama K, Wada A, Suqihara M, Kurioka S, Hayashi K, Hayashi T, et al. Potential hippocampal region atrophy in diabetes type 2: a voxel-based morphometry VSRAD study. Jpn J Radiol. 2010;28(4):266–72.
56. Kumar A, Gupta R, Thomas A, Ajilore O, Hellemann G. Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression. Arch Gen Psychiatry. 2009;66(3):324–30.
57. Masaki T, Anan F, Shimomura T, Fujiki M, Saikawa T, Yoshimatsu H. Association between hippocampal volume and serum adiponectin in patients with type 2 diabetes. Metab Clin Exp. 2012;61:1197–200.
58. Novak V, Zhao P, Manor B, Sejdic E, Alsop D, Abduljalil A, et al. Adhesion molecules, altered vasoreactivity, and brain atrophy in type 2 diabetes. Diabetes Care. 2011;34:2438–41.
59. Tan ZS, Beiser AS, Fox CS, Au R, Himali JJ, Debette S. Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults. Diabetes Care. 2011;34:1766–70.
60. Reijmer YD, van den Berg E, de Bresser J, Kessels RPC, Kappelle LJ, Algra A, et al. Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors. Diabetes Metab Res Rev. 2011;27:195–202.
61. Reijmer YD, Brundel M, de Bresser J, Kappelle LJ, Leemans A, Biessels GJ, et al. Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes. Diabetes Care. 2013;36:137–44.
62. Musen G, Jacobson AM, Bolo NR, Simonson DC, Shenton ME, McCartney RL, et al. Resting-state brain functional connectivity is altered in type 2 diabetes. Diabetes. 2012;61:2375–9.
63. Zhou H, Lu W, Shi Y, Bai F, Chang J, Yuan Y, et al. Impairments in cognition and resting-state connectivity of the hippocampus in elderly subjects with type 2 diabetes. Neurosci Lett. 2010;473:5–10.
64. Caetano SC, Kaur S, Brambilla P, Nicoletti M, Hatch JP, Sassi RB, et al. Smaller cingulate volumes in unipolar depressed patients. Biol Psychiatry. 2006;59:702–6.
65. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148(3):293–300.
66. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–9.
67. Wong RHX, Scholey A, Howe, PRC. Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus: a review with implications for future intervention studies. Curr Diab Rep. (In Press).
68. Kumar A, Haroon E, Darwin C, Pham D, Ajilore O, Rodriguez G, et al. Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging. 2008;27(1):14–9.
69. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004;26(8):1044–80.